On April 24th, seven departments including the Ministry of Industry and Information Technology, the Ministry of Commerce, the National Health Commission, the National Healthcare Security Administration, the National Data Bureau, the National Administration of Traditional Chinese Medicine, and the National Medical Products Administration jointly released the "Implementation Plan for the Digital Transformation of the Pharmaceutical Industry (2025-2030)" (hereinafter referred to as the "Implementation Plan"). The digital transformation of the pharmaceutical industry is an important path to promote high-quality development of the pharmaceutical industry, ensure public health, and build a healthy China. Against the backdrop of rapid iteration of global pharmaceutical technology and intensified industry competition, traditional production models are no longer able to meet the needs of industry development. Cutting edge technologies such as artificial intelligence can solve pain points in pharmaceutical research and development, restructure production processes, optimize circulation systems, and bring new opportunities for the development of the pharmaceutical industry. In recent years, a series of documents such as the "14th Five Year Plan" for the development of the pharmaceutical industry, the "Action Plan for High Quality Development of the Pharmaceutical Industry (2023-2025)", the "Action Plan for Digital Transformation of Manufacturing Industry", and the "Opinions on Comprehensively Deepening the Reform of Drug and Medical Device Supervision to Promote High Quality Development of the Pharmaceutical Industry" have been issued to further accelerate the promotion and application of digital and intelligent technologies in the pharmaceutical industry. In addition, the Implementation Plan also proposes development goals for the next two stages. By 2027, significant progress will be made in the digital transformation of the pharmaceutical industry, and the competitiveness and quality management level of the entire pharmaceutical industry chain driven by digital technology will be significantly improved. By 2030, large-scale pharmaceutical industry enterprises will basically achieve full coverage of digital transformation, significantly improve their ability to integrate and innovate digital technology, further improve the data system of the entire pharmaceutical industry chain, and further enhance the ecological system of digital transformation in the pharmaceutical industry. Yu Xiaohui, President of the China Academy of Information and Communications Technology, told reporters that drug safety is directly related to the life and health of the people, and the digital transformation provides strong technical support for the full life cycle management of drugs. Through digital means such as electronic batch recording and full traceability systems, enterprises can achieve precise control of the production process and real-time monitoring of quality data. Currently, the digital transformation of the pharmaceutical industry has shown a strong trend of breakthroughs across the entire chain. In the field of research and development, AI assisted target screening, compound synthesis pathway prediction and other technologies are used to revolutionize traditional research and development models. The deep integration of gene sequencing and clinical data drives precision drug development, and virtual experimental tools greatly improve research and development efficiency; The production process is centered around intelligent transformation, relying on digital workshops to achieve real-time and precise control of process parameters, and building an intelligent quality traceability system covering the entire lifecycle of drugs; The circulation field enhances the resilience of the supply chain through intelligent logistics and blockchain traceability systems, and the digital marketing network effectively expands the coverage of grassroots pharmaceutical services. These breakthroughs are effectively driving the pharmaceutical industry to accelerate its evolution towards high-end, intelligent, and green directions. Recently, reporters visited Beijing Huakan Biotechnology Co., Ltd. (hereinafter referred to as "Huakan Biotechnology") to gain a deeper understanding of its research and development achievements in the pharmaceutical industry's digital intelligence products - the "3D Cell Intelligent Manufacturing Platform". Yan Xiaojun, co-founder and CTO of Huakan Biotechnology, introduced that the one-stop customized and large-scale cell expansion solution built on this platform can achieve large-scale, automated, intelligent, and enclosed production and preparation of cell drugs and their derivatives, and has helped global customers establish advanced cell drug production lines. The digitalization application service enterprise is facing favorable development. The Consumer Goods Industry Department of the Ministry of Industry and Information Technology introduced that the "Implementation Plan" deploys 14 key tasks in four aspects. One is to strengthen the research and application of digital intelligence products in the pharmaceutical industry, integrate and release the value of medical data elements, upgrade information infrastructure, and deepen the application of artificial intelligence empowerment in the "Digital Intelligence Technology Empowerment Action". Secondly, in the "Digital Transformation Promotion Action", we will promote excellent scenarios of typical digital technology applications, cultivate outstanding enterprises in digital transformation, and build digital pharmaceutical industry parks. The third is to strengthen the guidance of standards, enhance quality support, cultivate innovative carriers, and strengthen the service team in the "Action Plan for Building a Smart Service System". The fourth is to explore new models of smart supervision, innovate new tools for smart supervision, and research new methods for smart supervision in the "Digital Supervision Enhancement Action". Specifically, the Implementation Plan focuses on multiple core areas such as pharmaceutical research and development, pharmaceutical production, business management decision-making, pharmaceutical quality and safety assurance, pharmaceutical circulation and traceability, and pharmaceutical contract research and development production services (CXO), implementing the promotion of digital transformation. It provides a detailed list of key elements such as data elements, knowledge models, tool software, and talent skills, laying a clear guiding path for collaborative cooperation between pharmaceutical enterprises and information technology service enterprises. This enables both parties to work together with targeted approaches to create digital application scenarios, thereby systematically promoting the digital transformation process of pharmaceutical enterprises. Zhang Cuixia, Chief Investment Advisor of Jufeng Investment, told reporters that with the official release of the "Implementation Plan", many enterprises serving the pharmaceutical industry chain will usher in development opportunities. For example, some companies that were originally inefficient in the research and development process can quickly launch innovative drugs by introducing intelligent target screening, drug molecule design and optimization, and other digital application scenarios, thus standing out in the fierce market competition and occupying a favorable position. At the same time, digital service companies can deepen cooperation with pharmaceutical companies to jointly promote the digital transformation of the pharmaceutical industry to new heights. In terms of fully exploring and unleashing the value of pharmaceutical data elements, the Implementation Plan proposes to encourage pharmaceutical enterprises, medical institutions, research institutes, etc. to work together to build a pharmaceutical industry big data platform, integrate and form high-quality datasets in research and development, production, clinical practice, big health and other fields, promote data classification and grading management, and pilot data element markets. Zheng Lei, Chief Economist of Samoyed Cloud Technology Group, analyzed to reporters that pharmaceutical companies control massive amounts of data in the process of drug production and research and development, medical institutions have accumulated rich clinical data resources, and research institutes have significant advantages in basic research and cutting-edge technology exploration. By utilizing the technical support of digital service enterprises and cooperating to build big data platforms, efficient integration and deep mining can be achieved, injecting strong impetus into the innovative development of the pharmaceutical industry. (New Society)